India’s startup gap persists
Observers say India remains a major manufacturing and generics player but still lacks deep-science biotech startup ecosystems, with funding and policy gaps slowing the translation of talent into high‑risk, high‑reward ventures. The critique emphasizes that scientific skill alone isn’t enough without supportive capital and translational infrastructure. (indiatoday.in)
India has built a big biotech industry, but founders and investors say the country still struggles to turn lab research into venture-backed deep-science startups. (indiatoday.in) The immediate trigger was an April 11, 2026 India Today report on a viral social media critique that argued India produces scientific talent but lacks the capital, policy support, and translational infrastructure needed for high-risk biotech ventures. The report centered on the gap between research capability and startup formation. (indiatoday.in) Official numbers show why the debate is not about scale alone. India’s bioeconomy reached $195.3 billion in 2025 and the country had more than 11,800 biotech startups by March 19, 2026, according to the India BioEconomy Report 2026 released by the government. (pib.gov.in) India is already a manufacturing power in medicines. The government says the country supplies 20% of the world’s generic medicines and ranks third globally in pharmaceutical production by volume, while industry data says India makes more than 60% of the world’s vaccines. (pib.gov.in, ibef.org) What critics are describing is a different part of the business. Deep-science biotech startups spend years turning a lab result into a product, and that stretch between proof in a lab and commercial production usually needs patient capital, incubators, testing facilities, and regulators that move on predictable timelines. (worldbank.org, mea.gov.in) The government has been trying to build that middle layer. The Union Cabinet approved the BioE3 policy on August 24, 2024 to back research, entrepreneurship, and high-performance biomanufacturing, and BIRAC says it has also built biofoundries, hubs, and other shared infrastructure. (pib.gov.in, birac.nic.in) More money was added on February 13, 2026, when the government announced the first national call under a ₹2,000 crore Biotechnology Industry Research Assistance Council-Research, Development and Innovation fund. Officials said the fund is meant to bridge the gap from lab-stage work to industrial scale-up over as long as five years. (pib.gov.in) BIRAC’s own dashboard shows both progress and the limits of the current system. It says its AcE Fund had committed ₹349 crore to biotech startups and enabled ₹1,560 crore in actual investment across 102 startups as of August 2025, while its broader programs had supported more than 5,000 startups and other beneficiaries. (birac.nic.in) Industry leaders say the weak spot is still late and clinical-stage financing. In comments published April 7, 2026, Biocon Executive Chairperson Kiran Mazumdar-Shaw said India faces thin venture participation, regulatory bottlenecks, and limited exit routes for companies that need years of spending before revenue arrives. (thehindubusinessline.com) That leaves India with a split-screen biotech story in 2026: strong manufacturing, fast bioeconomy growth, and rising startup counts on one side, and a thinner pipeline of venture-funded deep-science companies on the other. The next test is whether new public money and policy can move more ideas from Indian labs into companies that survive the long road to market. (pib.gov.in, pib.gov.in, indiatoday.in)
